• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

    2/9/23 11:07:45 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email
    SC 13G/A 1 tv0316-artivioninc.htm SCHEDULE 13G/A artivioninc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Artivion Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  228903100

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  228903100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    58,742

    7.  SOLE DISPOSITIVE POWER

    2,717,167

    8.  SHARED DISPOSITIVE POWER

    91,973

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,809,140

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.97%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Artivion Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1655 Roberts Boulevard NW
    Kennesaw, GA 30144-3632

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    228903100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $AORT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    8/13/2025$38.79Buy → Neutral
    Ladenburg Thalmann
    6/17/2025$35.00Buy
    Canaccord Genuity
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artivion downgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann downgraded Artivion from Buy to Neutral and set a new price target of $38.80

    8/13/25 8:00:59 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Artivion with a new price target

    Canaccord Genuity initiated coverage of Artivion with a rating of Buy and set a new price target of $35.00

    6/17/25 7:48:51 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    JMP Securities initiated coverage on Artivion with a new price target

    JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

    10/23/24 6:17:27 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artivion Reports Second Quarter 2025 Financial Results

    Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basisNet income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025Adjusted EBITDA increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024Exchanged $99.5 million in principal amount of outstanding convertible senior notes due July 1, 2025 for common stock, resulting in the effective retirement of previously issued

    8/7/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion to Participate in Upcoming Investor Conferences

    ATLANTA, July 30, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 10:30 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page.  An archived copy of the

    7/30/25 4:10:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results

    ATLANTA, July 24, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2025 financial results will be released on Thursday, August 7, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 862-298-0702 a few minu

    7/24/25 4:10:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 23, 2023 - FDA Roundup: May 23, 2023

    For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

    5/23/23 4:06:19 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/5/25 4:01:01 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    SEC Filings

    View All

    Artivion Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    8/11/25 1:18:02 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Artivion Inc.

    S-8 - ARTIVION, INC. (0000784199) (Filer)

    8/8/25 2:27:57 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Artivion Inc.

    10-Q - ARTIVION, INC. (0000784199) (Filer)

    8/8/25 11:30:09 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Mackin James P sold $528,988 worth of shares (12,500 units at $42.32), decreasing direct ownership by 1% to 852,783 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    8/19/25 11:28:10 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SVP, General Counsel Holloway Jean F exercised 16,975 shares at a strike of $26.24 and sold $1,004,610 worth of shares (23,356 units at $43.01), decreasing direct ownership by 4% to 172,129 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    8/14/25 9:58:42 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Davis John E exercised 10,802 shares at a strike of $26.24 and sold $471,756 worth of shares (10,802 units at $43.67) (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    8/14/25 9:56:50 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Leadership Updates

    Live Leadership Updates

    View All

    Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

    Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

    12/6/23 4:15:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Sequana Medical announces results of Special General Meeting of Shareholders

    PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

    6/26/23 12:00:00 PM ET
    $AORT
    $PHAR
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elizabeth Hoff Joins Artivion Board of Directors

    ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

    9/29/22 4:10:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Financials

    Live finance-specific insights

    View All

    Artivion Reports Second Quarter 2025 Financial Results

    Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basisNet income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025Adjusted EBITDA increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024Exchanged $99.5 million in principal amount of outstanding convertible senior notes due July 1, 2025 for common stock, resulting in the effective retirement of previously issued

    8/7/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports First Quarter 2025 Financial Results

    First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

    5/5/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

    Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju

    2/24/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artivion Inc.

    SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

    11/8/24 10:29:29 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Artivion Inc.

    SC 13G - ARTIVION, INC. (0000784199) (Subject)

    3/11/24 5:45:25 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

    SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

    2/14/24 6:18:56 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care